Helen Varsos

842 total citations
15 papers, 128 citations indexed

About

Helen Varsos is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Helen Varsos has authored 15 papers receiving a total of 128 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Hematology and 5 papers in Molecular Biology. Recurrent topics in Helen Varsos's work include CAR-T cell therapy research (12 papers), Multiple Myeloma Research and Treatments (8 papers) and Protein Degradation and Inhibitors (5 papers). Helen Varsos is often cited by papers focused on CAR-T cell therapy research (12 papers), Multiple Myeloma Research and Treatments (8 papers) and Protein Degradation and Inhibitors (5 papers). Helen Varsos collaborates with scholars based in United States, Belgium and Israel. Helen Varsos's co-authors include Lester Porter, William H. Liggett, Jeffrey Patton, Adam D. Cohen, Yaël C. Cohen, Jordan M. Schecter, Tonia Nesheiwat, Mounzer Agha, Muhammad Akram and Hartmut Goldschmidt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Oncologist.

In The Last Decade

Helen Varsos

13 papers receiving 123 citations

Peers

Helen Varsos

HEMAT

ONCOL

IMMUN

Danielle Trancucci United States

Xinli Pang China

Chiara Caraccio United States

Grzegorz Charliński Poland

Puneeth Guruprasad United States

Christopher Maisel United States

Gian Matteo Pica France

Ariel Grajales‐Cruz United States

Ekaterina Postovalova United States

Danielle Trancucci United States

Helen Varsos

89 ×1.1

HEMAT

96 ×1.2

ONCOL

38 ×0.9

20 ×0.7

IMMUN

6 ×0.4

Citations per year, relative to Helen Varsos Helen Varsos (= 1×) peers Danielle Trancucci

Countries citing papers authored by Helen Varsos

Since Specialization

Citations

This map shows the geographic impact of Helen Varsos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Varsos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Varsos more than expected).

Fields of papers citing papers by Helen Varsos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Varsos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Varsos. The network helps show where Helen Varsos may publish in the future.

Co-authorship network of co-authors of Helen Varsos

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Varsos. A scholar is included among the top collaborators of Helen Varsos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Varsos. Helen Varsos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Arnulf, Bertrand, Tessa Kerre, Mounzer Agha, et al.. (2024). Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.. Journal of Clinical Oncology. 42(16_suppl). 7505–7505. 2 indexed citations

Cohen, Adam D., Mounzer Agha, Jesús F. San Miguel, et al.. (2024). PCR134 Psychometric Properties of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Analysis of Phase 2 CARTITUDE-2 Study Cohorts A, B, and C. Value in Health. 27(6). S320–S320.

Einsele, Hermann, Adam D. Cohen, Michel Delforge, et al.. (2022). Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.. Journal of Clinical Oncology. 40(16_suppl). 8020–8020. 5 indexed citations

Hillengaß, Jens, Adam D. Cohen, Michel Delforge, et al.. (2022). P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA. HemaSphere. 6. 849–850. 2 indexed citations

Cohen, Ann D., Michel Delforge, Jens Hillengaß, et al.. (2022). P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY. HemaSphere. 6. 15–15. 8 indexed citations

Agha, Mounzer, Adam D. Cohen, Yaël C. Cohen, et al.. (2022). MM-153 Phase 2 CARTITUDE-2 Study (Cohort B): Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients With Multiple Myeloma (MM) and Early Relapse After Initial Therapy. Clinical Lymphoma Myeloma & Leukemia. 22. S408–S409. 1 indexed citations

Einsele, Hermann, Michel Delforge, Hartmut Goldschmidt, et al.. (2022). OAB-045: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (cilta-cel) in lenalidomide-refractory multiple myeloma after 1–3 prior lines of therapy: CARTITUDE-2 Cohort A. Clinical Lymphoma Myeloma & Leukemia. 22. S27–S28. 1 indexed citations

Hillengaß, Jens, Adam D. Cohen, Michel Delforge, et al.. (2022). MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT). Clinical Lymphoma Myeloma & Leukemia. 22. S411–S411. 5 indexed citations

Donk, Niels W.C.J. van de, Mounzer Agha, Adam D. Cohen, et al.. (2022). Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B.. Journal of Clinical Oncology. 40(16_suppl). 8029–8029. 14 indexed citations

10.

Einsele, Hermann, Niels W.C.J. van de Donk, Bertrand Arnulf, et al.. (2021). CARTITUDE-2: Phase 2 Multicohort Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma. Transplantation and Cellular Therapy. 27(3). S433–S434.

11.

Cohen, Yaël C., Adam D. Cohen, Michel Delforge, et al.. (2021). Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2. Blood. 138(Supplement 1). 3866–3866. 20 indexed citations

12.

Agha, Mounzer, Adam D. Cohen, Deepu Madduri, et al.. (2021). CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.. Journal of Clinical Oncology. 39(15_suppl). 8013–8013. 22 indexed citations

13.

Einsele, Hermann, Samir Parekh, Deepu Madduri, et al.. (2021). Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2.. Journal of Clinical Oncology. 39(15_suppl). 8028–8028. 3 indexed citations

14.

Steensma, David P., Uwe Platzbecker, Koen Van Eygen, et al.. (2018). Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive. Blood. 132(Supplement 1). 463–463. 9 indexed citations

15.

Patton, Jeffrey, et al.. (2004). Epoetin Alfa 60,000 U Once Weekly Followed by 120,000 U Every 3 Weeks Increases and Maintains Hemoglobin Levels in Anemic Cancer Patients Undergoing Chemotherapy. The Oncologist. 9(1). 90–96. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact